5CV — CureVac NV Income Statement
0.000.00%
Last trade - 00:00
- €696.68m
- €529.46m
- €53.76m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 17.4 | 48.9 | 103 | 67.4 | 53.8 |
Cost of Revenue | |||||
Gross Profit | -10.6 | 34.7 | -135 | -91.6 | -62.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 117 | 159 | 515 | 317 | 328 |
Operating Profit | -99.5 | -110 | -412 | -249 | -274 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -100 | -130 | -412 | -249 | -260 |
Provision for Income Taxes | |||||
Net Income After Taxes | -99.9 | -129 | -412 | -249 | -260 |
Net Income Before Extraordinary Items | |||||
Net Income | -99.9 | -129 | -412 | -249 | -260 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -99.9 | -129 | -412 | -249 | -260 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.566 | -0.716 | -2.35 | -1.17 | -1.03 |
Dividends per Share |